Microenvironmental abnormalities induced by viral cooperation: Impact on lymphomagenesis

Seminars in Cancer Biology

Volumn 34, Issue , 2015, Pages 70-80

  De Paoli, Paolo ^a   Carbone, Antonino ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

Epstein Barr virus; Human immunodeficiency virus; Kaposi's sarcoma herpesvirus; Lymphomagenesis; Viral cooperation

Indexed keywords

CD163 ANTIGEN; CD3 ANTIGEN; CD34 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CD57 ANTIGEN; CD68 ANTIGEN; CD8 ANTIGEN; CHEMOKINE; GRANZYME B; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 6; PERFORIN; PROGRAMMED DEATH 1 RECEPTOR; TRANSCRIPTION FACTOR FOXP3;

ANTIANGIOGENIC THERAPY; B LYMPHOCYTE; CARCINOGENESIS; EBNA 2 GENE; ENDOTHELIUM CELL; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; FIBROBLAST; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; KAPOSI SARCOMA; KIE2 GENE; LANA GENE; LMP 1 GENE; LYMPHOMA; LYMPHOMAGENESIS; MACROPHAGE; NONHUMAN; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; REVIEW; RTA GENE; STROMA CELL; T CELL LEUKEMIA; T LYMPHOCYTE; TAT GENE; TUMOR MICROENVIRONMENT; VIRAL COOPERATION; VIRAL PHENOMENA AND FUNCTIONS; VIRUS GENE; VIRUS PATHOGENESIS; VPU GENE; ADVERSE EFFECTS; ANIMAL; COMPLICATION; IMMUNOLOGY; IMMUNOSURVEILLANCE; LYMPHOPROLIFERATIVE DISORDERS; METABOLISM; MIXED INFECTION; MOLECULAR DIAGNOSIS; PATHOLOGY; PHYSIOLOGY; TRANSPLANTATION; TUMOR VIRUS; TUMOR VIRUS INFECTIONS; VIROLOGY; VIRUS CELL TRANSFORMATION;

ANIMALS; CELL TRANSFORMATION, VIRAL; COINFECTION; HUMANS; IMMUNOLOGIC SURVEILLANCE; LYMPHOMA; LYMPHOPROLIFERATIVE DISORDERS; MOLECULAR DIAGNOSTIC TECHNIQUES; ONCOGENIC VIRUSES; TRANSPLANTATION; TUMOR MICROENVIRONMENT; TUMOR VIRUS INFECTIONS;

EID: 84942295101     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2015.03.009     Document Type: Review

References (88)

1. Engels E.A. Infectious agents as causes of non-Hodkin Lymphoma. Cancer Epidemiol Biomark Prev 2007, 16(3):401-404.
2. Bouvard V., Baan R., Straif K., Grosse Y., Secretan B., El Ghissassi F., et al. A review of human carcinogens - Part B: biological agents. Lancet Oncol 2009, 10(4):321-322.
3. Gopal S., Achenbach C.J., Yanik E.L., Dittmer D.P., Eron J.J., Engels E.A., et al. J Clin Oncol 2014, pii:JCO.2014.57.0309. [Epub ahead of print]. PubMed PMID: 25002715.
4. De Paoli P., Carbone A. Carcinogenic viruses and solid cancers without sufficient evidence of causal association. Int J Cancer 2013, 133(7):1517-1529. Epub 2013 Jan 18. Review. PubMed PMID: 23280523. 10.1002/ijc.27995.
5. De Paoli P., Carbone A. Pathogenesis of HIV-associated cancer. J Clin Oncol 2014, pii: JCO.2014.56.0680. [Epub ahead of print]. PubMed PMID: 25002732.
6. Marcucci F., Mele A. Hepatitis viruses and non-Hodgkin lymphoma: epidemiology, mechanisms of tumorigenesis, and therapeutic opportunities. Blood 2011, 117(6):1792-1798. Epub 2010 Oct 19. Review. PubMed PMID: 20959600. 10.1182/blood-2010-06-275818.
7. IARC Monographs on the evaluation of carcinogenic risks to humans. Vol. 100 Part B: Biological Agents 2012, The International Agency for Research on Cancer, Lyon, France.
8. Carbone A., Vaccher E., Gloghini A., Pantanowitz L., Abayomi A., De Paoli P., et al. Diagnosis and management of lymphomas and other cancers in HIV-infected patients. Nat Rev Clin Oncol 2014, 11(April (4)):223-238. Epub 2014 Mar 11. PubMed PMID: 24614140. 10.1038/nrclinonc.2014.31.
9. Castillo J.J., Reagan J.L., Bishop K.D., Apor E. Viral lymphomagenesis: from pathophysiology to the rationale for novel therapies. Br J Haematol 2014, 165(3):300-315. Epub 2014 Feb 18. Review. PubMed PMID: 24533596. 10.1111/bjh.12788.
10. Boshoff C. Unraveling virus-induced lymphomagenesis. J Clin Invest 2011, 121(3):838-841. Epub 2011 Feb 21. PubMed PMID: 21339638; PubMed Central PMCID: PMC3046640. 10.1172/JCI46499.
11. Carbone A., De Paoli P., Gloghini A., Vaccher E. KSHV-associated multicentric Castleman disease: a tangle of different entities requiring multitarget treatment strategies. Int J Cancer 2014, [Epub ahead of print]. PubMed PMID: 24771491. 10.1002/ijc.28923.
12. Scott D.W., Gascoyne R.D. The tumour microenvironment in B cell lymphomas. Nat Rev Cancer 2014, 14(August (8)):517-534. Epub 2014 Jul 10. Review. PubMed PMID: 25008267. 10.1038/nrc3774.
13. Shirogane Y., Watanabe S., Yanagi Y. Cooperation between different RNA virus genomes produces a new phenotype. Nat Commun 2012, 3:1235. PubMed PMID: 23212364. 10.1038/ncomms2252.
14. Shirogane Y., Watanabe S., Yanagi Y. Cooperation: another mechanism of viral evolution. Trends Microbiol 2013, 21(July (7)):320-324. Epub 2013 Jun 11. PubMed PMID: 23764388. 10.1016/j.tim.2013.05.004.
15. Mesri E.A., Feitelson M.A., Munger K. Human viral oncogenesis: a cancer hallmarks analysis. Cell Host Microbe 2014, 15(3):266-282. PubMed PMID: 24629334; PubMed Central PMCID: PMC3992243. 10.1016/j.chom.2014.02.011.
16. Rickinson A.B. Co-infections, inflammation and oncogenesis: future directions for EBV research. Semin Cancer Biol 2014, 26:99-115. Epub 2014 Apr 18. PubMed PMID: 24751797. 10.1016/j.semcancer.2014.04.004.
17. Gulley M.L., Tang W. Laboratory assays for Epstein-Barr virus-related disease. J Mol Diagn 2008, 10(July (4)):279-292. Epub 2008 Jun 13. Review. PubMed PMID: 18556771; PubMed Central PMCID: PMC2438195. 10.2353/jmoldx.2008.080023.
18. Li C., Chen R.S., Hung S.K., Lee Y.T., Yen C.Y., Lai Y.W., et al. Detection of Epstein-Barr virus infection and gene expression in human tumors by microarray analysis. J Virol Methods 2006, 133(May (2)):158-166. Epub 2005 Dec 27. PubMed PMID: 16384612.
19. Carbone A., De Paoli P. Cancers related to viral agents that have a direct role in carcinogenesis: pathological and diagnostic techniques. J Clin Pathol 2012, 65(August (8)):680-686. Epub 2012 Apr 11. Review. PubMed PMID: 22496514. 10.1136/jclinpath-2012-200717.
20. De Paoli P., Pratesi C., Bortolin M.T. The Epstein Barr virus DNA levels as a tumor marker in EBV-associated cancers. J Cancer Res Clin Oncol 2007, 133(November (11)):809-815. Epub 2007 Jul 25. Review. PubMed PMID: 17653573.
21. Carbone A., Cesarman E., Spina M., Gloghini A., Schulz T.F. HIV-associated lymphomas and gamma-herpesviruses. Blood 2009, 113(6):1213-1224. Epub 2008 Oct 27. Review. PubMed PMID: 18955561. 10.1182/blood-2008-09-180315.
22. Carbone A., Gloghini A., Vaccher E., Cerri M., Gaidano G., Dalla-Favera R., et al. Kaposi's sarcoma-associated herpesvirus/human herpesvirus type 8-positive solid lymphomas: a tissue-based variant of primary effusion lymphoma. J Mol Diagn 2005, 7(February (1)):17-27. PubMed PMID: 15681470; PubMed Central PMCID: PMC1876263.
23. Chadburn A., Wilson J., Wang Y.L. Molecular and immunohistochemical detection of Kaposi Sarcoma Herpesvirus/human herpesvirus-8. Methods Mol Biol 2013, 999:245-256. PubMed PMID: 23666704. 10.1007/978-1-62703-357-2_18.
24. Boulanger E., Duprez R., Delabesse E., Gabarre J., Macintyre E., Gessain A. Mono/oligoclonal pattern of Kaposi Sarcoma-associated herpesvirus (KSHV/HHV-8) episomes in primary effusion lymphoma cells. Int J Cancer 2005, 115(4):511-518. PubMed PMID: 15700304.
25. Sakakibara S., Tosato G. Viral interleukin-6: role in Kaposi's sarcoma-associated herpesvirus: associated malignancies. J Interferon Cytokine Res 2011, 31(November (11)):791-801. Epub 2011 Jul 18. Review. PubMed PMID: 21767154; PubMed Central PMCID: PMC3216071. 10.1089/jir.2011.0043.
26. Simonelli C., Tedeschi R., Gloghini A., Talamini R., Bortolin M.T., Berretta M., et al. Plasma HHV-8 viral load in HHV-8-related lymphoproliferative disorders associated with HIV infection. J Med Virol 2009, 81(May (5)):888-896. PubMed PMID: 19319955. 10.1002/jmv.21349.
27. Breen E.C., Hussain S.K., Magpantay L., Jacobson L.P., Detels R., Rabkin C.S., et al. B-cell stimulatory cytokines and markers of immune activation are elevated several years prior to the diagnosis of systemic AIDS-associated non-Hodgkin B-cell lymphoma. Cancer Epidemiol Biomark Prev 2011, 20(July (7)):1303-1314. Epub 2011 Apr 28. PubMed PMID: 21527584; PubMed Central PMCID: PMC3132317. 10.1158/1055-9965.EPI-11-0037.
28. Liapis K., Clear A., Owen A., Coutinho R., Greaves P., Lee A.M., et al. The microenvironment of AIDS-related diffuse large B-cell lymphoma provides insight into the pathophysiology and indicates possible therapeutic strategies. Blood 2013, 122(3):424-433. Epub 2013 May 7. PubMed PMID: 23652804; PubMed Central PMCID: PMC3716203. 10.1182/blood-2013-03-488171.
29. Sica A., Larghi P., Mancino A., Rubino L., Porta C., Totaro M.G., et al. Macrophage polarization in tumour progression. Semin Cancer Biol 2008, 18(October (5)):349-355. Epub 2008 Mar 26. 10.1016/j.semcancer.2008.03.004.
30. Bortolin M.T., Tedeschi R., Bidoli E., Zanussi S., Pratesi C., Vaccher E., et al. Multiplex analysis of blood cytokines as a prognostic tool in HIV related non-Hodgkin lymphoma patients: a potential role of interleukin-7. Cytokine 2012, 60(October (1)):90-95. Epub 2012 Jul 12. PubMed PMID: 22795293. 10.1016/j.cyto.2012.06.022.
31. Yang H., Yorke E., Hancock G., Clutton G., Sande N., Angus B., et al. Improved quantification of HIV-1-infected CD4+ T cells using an optimised method of intracellular HIV-1 gag p24 antigen detection. J Immunol Methods 2013, 391(1-2):174-178. Epub 2013 Mar 13. PubMed PMID: 23500782. 10.1016/j.jim.2013.03.001.
32. Bagasra O., Pomerantz R.J. In situ polymerase chain reaction and HIV-1. Clin Lab Med 1994, 14(June (2)):351-365. Review. PubMed PMID: 7924195.
33. Huysentruyt L.C., McGrath M.S. The role of macrophages in the development and progression of AIDS-related non-Hodgkin lymphoma. J Leukoc Biol 2010, 87(April (4)):627-632. Epub 2009 Dec 30. Review. PubMed PMID: 20042471; PubMed Central PMCID: PMC2858304. 10.1189/jlb.0809564.
34. Coupland S.E. The challenge of the microenvironment in B-cell lymphomas. Histopathology 2011, 58(January (1)):69-80. Review. PubMed PMID: 21261684. 10.1111/j.1365-2559.2010.03706.x.
35. Lenz G., Wright G., Dave S.S., Xiao W., Powell J., Zhao H., et al. Lymphoma/Leukemia molecular profiling project. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008, 359(22):2313-2323. PubMed PMID: 19038878. 10.1056/NEJMoa0802885.
36. Preiksaitis J.K., Keay S. Diagnosis and management of posttransplant lymphoproliferative disorder in solid-organ transplant recipients. Clin Infect Dis 2001, 33(Suppl. 1):S38-S46. Review. PubMed PMID: 11389521.
37. Morscio J., Dierickx D., Tousseyn T. Molecular pathogenesis of B-cell posttransplant lymphoproliferative disorder: what do we know so far?. Clin Dev Immunol 2013, 2013:150835. Epub 2013 Apr 14. Review. PubMed PMID: 23690819; PubMed Central PMCID: PMC3649442. 10.1155/2013/150835.
38. Ishitsuka K., Tamura K. Human T-cell leukaemia virus type I and adult T-cell leukaemia-lymphoma. Lancet Oncol 2014, 15(October (11)):e517-e526. Review. PubMed PMID: 25281470. 10.1016/S1470-2045(14)70202-5.
39. Matsuoka M., Jeang K.T. Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nat Rev Cancer 2007, 7(April (4)):270-280. Review. PubMed PMID: 17384582.
40. Tedeschi R., Enbom M., Bidoli E., Linde A., De Paoli P., Dillner J. Viral load of human herpesvirus 8 in peripheral blood of human immunodeficiency virus-infected patients with Kaposi's sarcoma. J Clin Microbiol 2001, 39(December (12)):4269-4273. PubMed PMID: 11724831; PubMed Central PMCID: PMC88535.
41. Berretta M., Garlassi E., Cacopardo B., Cappellani A., Guaraldi G., Cocchi S., et al. Hepatocellular carcinoma in HIV-infected patients: check early, treat hard. Oncologist 2011, 16(9):1258-1269. Epub 2011 Aug 25. PubMed PMID: 21868692; PubMed Central PMCID: PMC3228175. 10.1634/theoncologist.2010-0400.
42. Terrier B., Costagliola D., Prevot S., Chavez H., Missy P., Rince P., et al. Characteristics of B-cell lymphomas in HIV/HCV-coinfected patients during the combined antiretroviral therapy era: an ANRS CO16 LYMPHOVIR cohort study. J Acquir Immune Defic Syndr 2013, 63(2):249-253. PubMed PMID: 23403861. 10.1097/QAI.0b013e31828a77f0.
43. Pagano J.S., Blaser M., Buendia M.A., Damania B., Khalili K., Raab-Traub N., et al. Infectious agents and cancer: criteria for a causal relation. Semin Cancer Biol 2004, 14(December (6)):453-471. Review. PubMed PMID: 15489139.
44. MacLeod R.A., Nagel S., Scherr M., Schneider B., Dirks W.G., et al. Human leukemia and lymphoma cell lines as models and resources. Curr Med Chem 2008, 15(4):339-359. Review. PubMed PMID: 18288989.
45. Carbone A., Cesarman E., Gloghini A., Drexler H.G. Understanding pathogenetic aspects and clinical presentation of primary effusion lymphoma through its derived cell lines. AIDS 2010, 24(4):479-490. Review. PubMed PMID: 20051807; PubMed Central PMCID: PMC3740588. 10.1097/QAD.0b013e3283365395.
46. Carbone A., Cilia A.M., Gloghini A., Capello D., Fassone L., Perin T., et al. Characterization of a novel HHV-8-positive cell line reveals implications for the pathogenesis and cell cycle control of primary effusion lymphoma. Leukemia 2000, 14(July (7)):1301-1309. PubMed PMID: 10914556.
47. Mack A.A., Sugden B. EBV is necessary for proliferation of dually infected primary effusion lymphoma cells. Cancer Res 2008, 68(17):6963-6968. PubMed PMID: 18757410; PubMed Central PMCID: PMC2587434. 10.1158/0008-5472.CAN-08-0627.
48. da Silva S.R., de Oliveira D.E. HIV, EBV and KSHV: viral cooperation in the pathogenesis of human malignancies. Cancer Lett 2011, 305(2):175-185. Epub 2011 Mar 12. Review. PubMed PMID: 21402436. 10.1016/j.canlet.2011.02.007.
49. Münz C. Viral infections in mice with reconstituted human immune system components. Immunol Lett 2014 Sep, 161(1):118-124. Epub 2014 Jun 2. PubMed PMID: 24953718. 10.1016/j.imlet.2014.05.012.
50. White R.E., Rämer P.C., Naresh K.N., Meixlsperger S., Pinaud L., Rooney C., et al. EBNA3B-deficient EBV promotes B cell lymphomagenesis in humanized mice and is found in human tumors. J Clin Invest 2012, 122(4):1487-1502. Epub 2012 Mar 12. PubMed PMID: 22406538; PubMed Central PMCID: PMC3314448. 10.1172/JCI58092.
51. Wang L.X., Kang G., Kumar P., Lu W., Li Y., Zhou Y., et al. Humanized-BLT mouse model of Kaposi's sarcoma-associated herpesvirus infection. Proc Natl Acad Sci U S A 2014, 111(8):3146-3151. Epub 2014 Feb 10. PubMed PMID: 24516154; PubMed Central PMCID: PMC3939909. 10.1073/pnas.1318175111.
52. Van Baarle D., Wolthers K.C., Hovenkamp E., Niesters H.G., Osterhaus A.D., Miedema F., et al. Absolute level of Epstein-Barr virus DNA in human immunodeficiency virus type 1 infection is not predictive of AIDS-related non-Hodgkin lymphoma. J Infect Dis 2002, 186(3):405-409. Epub 2002 Jul 17. PubMed PMID: 12134237.
53. Piriou E., van Dort K., Otto S., van Oers M.H., van Baarle D. Tight regulation of the Epstein-Barr virus setpoint: interindividual differences in Epstein-Barr virus DNA load are conserved after HIV infection. Clin Infect Dis 2008, 46(2):313-316. PubMed PMID: 18171268. 10.1086/524079.
54. Piriou E.R., van Dort K., Nanlohy N.M., Miedema F., van Oers M.H., van Baarle D. Altered EBV viral load setpoint after HIV seroconversion is in accordance with lack of predictive value of EBV load for the occurrence of AIDS-related non-Hodgkin lymphoma. J Immunol 2004, 172(11):6931-6937. PubMed PMID: 15153512.
55. Richard Y., Amiel C., Jeantils V., Mestivier D., Portier A., Dhello G., et al. Changes in blood B cell phenotypes and Epstein-Barr virus load in chronically human immunodeficiency virus-infected patients before and after antiretroviral therapy. J Infect Dis 2010, 202(9):1424-1434. PubMed PMID: 20874514. 10.1086/656479.
56. Seaberg E.C., Wiley D., Martínez-Maza O., Chmiel J.S., Kingsley L., Tang Y., et al. Multicenter AIDS Cohort Study (MACS). Cancer incidence in the multicenter AIDS Cohort Study before and during the HAART era: 1984 to 2007. Cancer 2010, 116(23):5507-5516. PMID: 20672354.
57. Engels E.A., Mbulaiteye S.M., Othieno E., Gomez M., Mathew S., Cesarman E., et al. Kaposi sarcoma-associated herpesvirus in non-Hodgkin lymphoma and reactive lymphadenopathy in Uganda. Hum Pathol 2007, 38(February (2)):308-314. PMID: 17097130.
58. Scala G., Quinto I., Ruocco M.R., Mallardo M., Ambrosino C., Squitieri B., et al. Epstein-Barr virus nuclear antigen 2 transactivates the long terminal repeat of human immunodeficiency virus type 1. J Virol 1993, 67(May (5)):2853-2861. PubMed PMID: 8386279; PubMed Central PMCID: PMC237610.
59. Lazzi S., Bellan C., De Falco G., Cinti C., Ferrari F., Nyongo A., et al. Expression of RB2/p130 tumor-suppressor gene in AIDS-related non-Hodgkin's lymphomas: implications for disease pathogenesis. Hum Pathol 2002, 33(July (7)):723-731. PubMed PMID: 12196924.
60. Colombrino E., Rossi E., Ballon G., Terrin L., Indraccolo S., Chieco-Bianchi L., et al. Human immunodeficiency virus type 1 Tat protein modulates cell cycle and apoptosis in Epstein-Barr virus-immortalized B cells. Exp Cell Res 2004, 295(2):539-548. PubMed PMID: 15093750.
61. Chen B.J., Chapuy B., Ouyang J., Sun H.H., Roemer M.G., Xu M.L., et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res 2013, 19(13):3462-3473. Epub 2013 May 14. PubMed PMID: 23674495; PubMed Central PMCID: PMC4102335. 10.1158/1078-0432.CCR-13-0855.
62. Planès R., BenMohamed L., Leghmari K., Delobel P., Izopet J., Bahraoui E. HIV-1 Tat protein induces PD-L1 (B7-H1) expression on dendritic cells through tumor necrosis factor alpha- and toll-like receptor 4-mediated mechanisms. J Virol 2014, 88(June (12)):6672-6689. Epub 2014 Apr 2. PubMed PMID: 24696476; PubMed Central PMCID: PMC4054384. 10.1128/JVI.00825-14.
63. Zenger E., Abbey N.W., Weinstein M.D., Kapp L., Reis J., Gofman I., et al. Injection of human primary effusion lymphoma cells or associated macrophages into severe combined immunodeficient mice causes murine lymphomas. Cancer Res 2002, 62(19):5536-5542. PubMed PMID: 12359765.
64. Romagnani S., Maggi E. Th1 versus Th2 responses in AIDS. Curr Opin Immunol 1994, 6(August (4)):616-622. Review. PubMed PMID: 7946051.
65. Kondo S., Seo S.Y., Yoshizaki T., Wakisaka N., Furukawa M., Joab I., et al. EBV latent membrane protein 1 up-regulates hypoxia-inducible factor 1alpha through Siah1-mediated down-regulation of prolyl hydroxylases 1 and 3 in nasopharyngeal epithelial cells. Cancer Res 2006, 66(20):9870-9877. PubMed PMID: 17047048.
66. Merat R., Amara A., Lebbe C., de The H., Morel P., Saib A. HIV-1 infection of primary effusion lymphoma cell line triggers Kaposi's sarcoma-associated herpesvirus (KSHV) reactivation. Int J Cancer 2002, 97(6):791-795. PubMed PMID: 11857356.
67. Mercader M., Nickoloff B.J., Foreman K.E. Induction of human immunodeficiency virus 1 replication by human herpesvirus 8. Arch Pathol Lab Med 2001, 125(June (6)):785-789. PubMed PMID: 11371231.
68. Huang C.C., Liang Y.C., Hsu K.S. Characterization of the mechanism underlying the reversal of long term potentiation by low frequency stimulation at hippocampal CA1 synapses. J Biol Chem 2001, 276(51):48108-48117. Epub 2001 Oct 25. PubMed PMID: 11679581.
69. Caccuri F., Giagulli C., Bugatti A., Benetti A., Alessandri G., Ribatti D., et al. HIV-1 matrix protein p17 promotes angiogenesis via chemokine receptors CXCR1 and CXCR2. Proc Natl Acad Sci U S A 2012, 109(36):14580-14585. Epub 2012 Aug 17. PubMed PMID: 22904195; PubMed Central PMCID: PMC3437870. 10.1073/pnas.1206605109.
70. Giagulli C., Caccuri F., Cignarella F., Lougaris V., Martorelli D., Bugatti A., et al. A CXCR1 haplotype hampers HIV-1 matrix protein p17 biological activity. AIDS 2014, 28(16):2355-2364. PubMed PMID: 25121556. 10.1097/QAD.0000000000000423.
71. Sun R., Lin S.F., Gradoville L., Yuan Y., Zhu F., Miller G. A viral gene that activates lytic cycle expression of Kaposi's sarcoma-associated herpesvirus. Proc Natl Acad Sci U S A 1998, 95(18):10866-10871. PubMed PMID: 9724796; PubMed Central PMCID: PMC27987.
72. Xu D., Coleman T., Zhang J., Fagot A., Kotalik C., Zhao L., et al. Epstein-Barr virus inhibits Kaposi's sarcoma-associated herpes virus lytic replication in primary effusion lymphomas. J Virol 2007, 81(June (11)):6068-6078. Epub 2007 Mar 21. PubMed PMID: 17376914; PubMed Central PMCID: PMC1900272.
73. Jiang Y., Xu D., Zhao Y., Zhang L. Mutual inhibition between Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus lytic replication initiators in dually-infected primary effusion lymphoma. PLoS ONE 2008, 3(2):e1569. PubMed PMID: 18253508; PubMed Central PMCID: PMC2215330. 10.1371/journal.pone.0001569.
74. Spadavecchia S., Gonzalez-Lopez O., Carroll K.D., Palmeri D., Lukac D.M. Convergence of Kaposi's sarcoma-associated herpesvirus reactivation with Epstein-Barr virus latency and cellular growth mediated by the notch signalling pathway in coinfected cells. J Virol 2010, 84(October (20)):10488-10500. Epub 2010 Aug 4. PubMed PMID: 20686042; PubMed Central PMCID: PMC2950570. 10.1128/JVI.00894-10.
75. Godfrey A., Anderson J., Papanastasiou A., Takeuchi Y., Boshoff C. Inhibiting primary effusion lymphoma by lentiviral vectors encoding short hairpin RNA. Blood 2005, 105(6):2510-2518. Epub 2004 Nov 30. PubMed PMID: 15572586.
76. Caselli E., Menegazzi P., Bracci A., Galvan M., Cassai E., Di Luca D. Human herpesvirus-8 (Kaposi's sarcoma-associated herpesvirus) ORF50 interacts synergistically with the tat gene product in transactivating the human immunodeficiency virus type 1 LTR. J Gen Virol 2001, 82(August (Pt 8)):1965-1970. PubMed PMID: 11458004.
77. Karijolich J., Zhao Y., Peterson B., Zhou Q., Glaunsinger B. Kaposi's sarcoma-associated herpesvirus ORF45 mediates transcriptional activation of the HIV-1 long terminal repeat via RSK2. J Virol 2014, 88(June (12)):7024-7035. Epub 2014 Apr 9. PubMed PMID: 24719417; PubMed Central PMCID: PMC4054375. 10.1128/JVI.00931-14.
78. de Oliveira D.E., Ballon G., Cesarman E. NF-kappaB signaling modulation by EBV and KSHV. Trends Microbiol 2010, 18(June (6)):248-257. Epub 2010 May 6. Review. PubMed PMID: 20452220. 10.1016/j.tim.2010.04.001.
79. Trivedi P., Takazawa K., Zompetta C., Cuomo L., Anastasiadou E., Carbone A., et al. Infection of HHV-8+ primary effusion lymphoma cells with a recombinant Epstein-Barr virus leads to restricted EBV latency, altered phenotype, and increased tumorigenicity without affecting TCL1 expression. Blood 2004, 103(1):313-316. Epub 2003 Sep 11. PubMed PMID: 12969959.
80. Kiss C., Nishikawa J., Takada K., Trivedi P., Klein G., Szekely L. T cell leukemia I oncogene expression depends on the presence of Epstein-Barr virus in the virus-carrying Burkitt lymphoma lines. Proc Natl Acad Sci U S A 2003, 100(8):4813-4818. Epub 2003 Apr 2. PubMed PMID: 12672960; PubMed Central PMCID: PMC153638.
81. Bentz G.L., Bheda-Malge A., Wang L., Shackelford J., Damania B., Pagano J.S. KSHV LANA and EBV LMP1 induce the expression of UCH-L1 following viral transformation. Virology 2014, 448:293-302. Epub 2013 Nov 8. PubMed PMID: 24314660; PubMed Central PMCID: PMC4157526. 10.1016/j.virol.2013.10.018.
82. Lester S.N., Li K. Toll-like receptors in antiviral innate immunity. J Mol Biol 2014, 426(6):1246-1264. Epub 2013 Dec 3. Review. PubMed PMID: 24316048; PubMed Central PMCID: PMC3943763. 10.1016/j.jmb.2013.11.024.
83. Iskra S., Kalla M., Delecluse H.J., Hammerschmidt W., Moosmann A. Toll-like receptor agonists synergistically increase proliferation and activation of B cells by Epstein-Barr virus. J Virol 2010, 84(April (7)):3612-3623. Epub 2010 Jan 20. PubMed PMID: 20089650; PubMed Central PMCID: PMC2838115. 10.1128/JVI.01400-09.
84. Bussey K.A., Reimer E., Todt H., Denker B., Gallo A., Konrad A., et al. The gammaherpesviruses Kaposi's sarcoma-associated herpesvirus and murine gammaherpesvirus 68 modulate the Toll-like receptor-induced proinflammatory cytokine response. J Virol 2014, 88(August (16)):9245-9259. Epub 2014 Jun 4. PubMed PMID: 24899179; PubMed Central PMCID: PMC4136288. 10.1128/JVI.00841-14.
85. Gopal S., Patel M.R., Achenbach C.J., Yanik E.L., Cole S.R., Napravnik S., et al. Lymphoma immune reconstitution inflammatory syndrome in the center for AIDS research network of integrated clinical systems cohort. Clin Infect Dis 2014, 59(2):279-286. Epub 2014 Apr 21. PubMed PMID: 24755860; PubMed Central PMCID: PMC4102912. 10.1093/cid/ciu270.
86. Uldrick T.S., Wyvill K.M., Kumar P., O'Mahony D., Bernstein W., Aleman K., et al. Phase II study of bevacizumab in patients with HIV-associated Kaposi's sarcoma receiving antiretroviral therapy. J Clin Oncol 2012, 30(13):1476-1483. Epub 2012 Mar 19. PubMed PMID: 22430271; PubMed Central PMCID: PMC3383119. 10.1200/JCO.2011.39.6853.
87. Fang H., Declerck Y.A. Targeting the tumor microenvironment: from understanding pathways to effective clinical trials. Cancer Res 2013, 73(16):4965-4977. Epub 2013 Aug 2. Review. PubMed PMID: 23913938; PubMed Central PMCID: PMC3815577. 10.1158/0008-5472.CAN-13-0661.
88. Jain R.K. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J Clin Oncol 2013, 31(17):2205-2218. Epub 2013 May 13. Review. PubMed PMID: 23669226; PubMed Central PMCID: PMC3731977. 10.1200/JCO.2012.46.3653.